Latent tuberculosis infection in a Malaysian prison: implications for a comprehensive integrated control program in prisons

BMC Public Health

Frederick L Altice²  Adeeba Kamarulzaman¹  Haider Abdulrazzaq Abed Al-Darraji³ 

[1] Department of Internal Medicine, Yale University School of Medicine, Section of Infectious Diseases, AIDS Program, New Haven, Connecticut, USA;Division of Epidemiology of Microbial Diseases, Yale University School of Public Health, New Haven, Connecticut, USA;Centre of Excellence for Research in AIDS, Faculty of Medicine, University of Malaya, Kuala Lumpur 59990, Malaysia

关键词: Integrated healthcare;    Isoniazid preventive therapy;    Substance use disorders;    Latent tuberculosis;    Malaysia;    Prisons;    HIV/AIDS;    Tuberculosis;   

Others  :  1161361
DOI  :  10.1186/1471-2458-14-22

 received in 2013-02-20, accepted in 2014-01-05,  发布年份 2014

【 摘 要 】

Background

Prisons continue to fuel tuberculosis (TB) epidemics particularly in settings where access to TB screening and prevention services is limited. Malaysia is a middle-income country with a relatively high incarceration rate of 138 per 100,000 population. Despite national TB incidence rate remaining unchanged over the past ten years, data about TB in prisons and its contribution to the overall national rates does not exist. This survey was conducted to address the prevalence of latent TB infection (LTBI) in Malaysia’s largest prison.

Methods

From July to December 2010, all HIV-infected and a comparative group of HIV-uninfected prisoners housed separately in Kajang prison were asked to participate in the survey after explaining the study protocol. Subjects providing informed consent were interviewed using a structured questionnaire followed by the placement of tuberculin skin test (TST) with 2 TU of PPD RT-23 to subjects not being treated for active TB. TST was read after 48-72 hours and indurations of ≥ 5 mm and ≥ 10 mm were considered positive among HIV-infected and HIV-uninfected subjects, respectively. Additionally, HIV-infected inmates underwent phlebotomy for CD4 lymphocyte count assessment. A logistic regression model was explored to determine factors associated with TST positivity.

Results

Overall, 286 subjects (138 HIV-infected and 148 HIV-uninfected) had complete data and TST results. The majority were men (95.1%), less than 40 years old (median age 36.0, SD 7.87), and Malaysians (93.3%). Most (82.5%) had been previously incarcerated and more than half (53.1%) reported sharing needles just prior to their incarceration. TST was positive in 88.8% (84.7% among HIV-infected and 92.5% among HIV-uninfected subjects) and was independently associated with being HIV-uninfected (AOR = 2.97, p = 0.01) and with frequent previous incarcerations (AOR = 1.22 for every one previous incarceration, p = 0.01) after adjusting for other potential confounding factors.

Conclusions

The prevalence of LTBI was extraordinary high in this sample of Malaysian prisoners, regardless of their age or HIV status. This warrants further examination of the size of the problem of TB in other congregate settings and the establishment of an evidence-based TB control program in Malaysian prisons with integrated TB, HIV and substance abuse components.

【 授权许可】

   
2014 Al-Darraji et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Basu S, Stuckler D, McKee M: Addressing institutional amplifiers in the dynamics and control of tuberculosis epidemics. Am J Trop Med Hyg 2011, 84(1):30-37.
• [2]Valway SE, Richards SB, Kovacovich J, Greifinger RB, Crawford JT, Dooley SW: Outbreak of multi-drug-resistant tuberculosis in a New York State prison, 1991. Am J Epidemiol 1994, 140(2):113-122.
• [3]Fazel S, Baillargeon J: The health of prisoners. Lancet 2011, 377(9769):956-965.
• [4]Coninx R, Maher D, Reyes H, Grzemska M: Tuberculosis in prisons in countries with high prevalence. BMJ 2000, 320(7232):440-442.
• [5]Johnstone-Robertson S, Lawn SD, Welte A, Bekker LG, Wood R: Tuberculosis in a South African prison - a transmission modelling analysis. S Afr Med J 2011, 101(11):809-813.
• [6]World Health Organisation (WHO): Tuberculosis Control in Prisons: A Manual for Programme Managers. Geneva: WHO; 2000.
• [7]Al-Darraji HAA, Kamarulzaman A, Altice FL: Isoniazid preventive therapy in correctional facilities: a systematic review [Review article]. Int J Tuberc Lung Dis 2012, 16(7):871-879.
• [8]Stuckler D, Basu S, McKee M, King L: Mass incarceration can explain population increases in TB and multidrug-resistant TB in European and central Asian countries. Proc Natl Acad Sci USA 2008, 105(36):13280-13285.
• [9]Vagenas P, Azbel L, Polonsky M, Kerimi N, Mamyrov M, Dvoryak S, Altice FL: A review of medical and substance use co-morbidities in central asian prisons: implications for HIV prevention and treatment. Drug Alcohol Depend 2013, 132(Suppl 1):S25-S31.
• [10]Baussano I, Williams BG, Nunn P, Beggiato M, Fedeli U, Scano F: Tuberculosis incidence in prisons: a systematic review. PLoS Med 2010, 7(12):e1000381.
• [11]World Health Organization (WHO): Global Tuberculosis Control: WHO Report 2011. Geneva: WHO Press; 2011.
• [12]Choi P, Kavasery R, Desai MM, Govindasamy S, Kamarulzaman A, Altice FL: Prevalence and correlates of community re-entry challenges faced by HIV-infected male prisoners in Malaysia. Int J STD AIDS 2010, 21(6):416-423.
• [13]Zahari MM, Hwan Bae W, Zainal NZ, Habil H, Kamarulzaman A, Altice FL: Psychiatric and substance abuse comorbidity among HIV seropositive and HIV seronegative prisoners in Malaysia. Am J Drug Alcohol Abuse 2010, 36(1):31-38.
• [14]World Health Organization (WHO): Assessment of compulsory treatment of people who use drugs in Cambodia, China, Malaysia and Viet Nam: an application of selected human rights principles. Western Pacific Regional Office: WHO; 2009.
• [15]Fu JJ, Bazazi AR, Altice FL, Mohamed MN, Kamarulzaman A: Absence of antiretroviral therapy and other risk factors for morbidity and mortality in Malaysian compulsory drug detention and rehabilitation centers. PloS One 2012, 7(9):e44249.
• [16]Suruhanjaya Hak Asasi Manusia Malaysia: The State Of Prisons And Immigration Detention Centres In Malaysia 2007 – 2008. 2008. http://www.suhakam.org.my/c/document_library/get_file?p_l_id=10408&folderId=236834&name=DLFE-237802.pdf webcite
• [17]Center for Disease Control (CDC), Infectious Disease Society of America (IDSA), American Thoracic Society (ATS): Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000, 49(RR-6):1-51.
• [18]Rafiza S, Rampal KG, Tahir A: Prevalence and risk factors of latent tuberculosis infection among health care workers in Malaysia. BMC Infect Dis 2011, 11:19. BioMed Central Full Text
• [19]Awofeso N: Prisons as social determinants of hepatitis C virus and tuberculosis infections. Public Health Rep 2010, 125(Suppl 4):25-33.
• [20]Hussain H, Akhtar S, Nanan D: Prevalence of and risk factors associated with Mycobacterium tuberculosis infection in prisoners, North West Frontier Province, Pakistan. Int J Epidemiol 2003, 32(5):794-799.
• [21]Nogueira PA, Abrahao RM, Galesi VM: Tuberculosis and latent tuberculosis in prison inmates. Revista de saude publica 2012, 46(1):119-127.
• [22]Adib SM, Al-Takash H, Al-Hajj C: Tuberculosis in lebanese jails: prevalence and risk factors. Eur J Epidemiol 1999, 15(3):253-260.
• [23]Chee CB, Teleman MD, Boudville IC, Wang YT: Contact screening and latent TB infection treatment in Singapore correctional facilities. Int J Tuberc Lung Dis 2005, 9(11):1248-1252.
• [24]Marco A, Sole N, Orcau A, Escribano M, del Bano L, Quintero S, Cayla JA: Prevalence of latent tuberculosis infection in inmates recently incarcerated in a men’s prison in Barcelona. Int J Tuberc Lung Dis 2012, 16(1):60-64.
• [25]Martin V, Guerra JM, Cayla JA, Rodriguez JC, Blanco MD, Alcoba M: Incidence of tuberculosis and the importance of treatment of latent tuberculosis infection in a Spanish prison population. Int J Tuberc Lung Dis 2001, 5(10):926-932.
• [26]Ritter C, Elger BS: Prevalence of positive tuberculosis skin tests during 5 years of screening in a Swiss remand prison. Int J Tuberc Lung Dis 2012, 16(1):65-69.
• [27]Carbonara S, Babudieri S, Longo B, Starnini G, Monarca R, Brunetti B, Andreoni M, Pastore G, De Marco V, Rezza G: Correlates of Mycobacterium tuberculosis infection in a prison population. Eur Respir J 2005, 25(6):1070-1076.
• [28]Lobato MN, Leary LS, Simone PM: Treatment for latent TB in correctional facilities: a challenge for TB elimination. Am J Prev Med 2003, 24(3):249-253.
• [29]Deiss RG, Rodwell TC, Garfein RS: Tuberculosis and illicit drug use: review and update. Clin Infect Dis 2009, 48(1):72-82.
• [30]Centers for Disease Control and Prevention (CDC): Guidelines for the investigation of contacts of persons with infectious tuberculosis; recommendations from the national tuberculosis controllers association and CDC. MMWR 2005, 54(No. RR-15):1-37.
• [31]Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, Walker AT, Friedland GH: A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989, 320(9):545-550.
• [32]Vinkeles Melchers NV, van Elsland SL, Lange JM, Borgdorff MW, van den Hombergh J: State of affairs of tuberculosis in prison facilities: a systematic review of screening practices and recommendations for best TB control. PLoS One 2013, 8(1):e53644.
• [33]Al-Darraji HA, Razak HA, Ng KP, Altice FL, Kamarulzaman A: The diagnostic performance of a single GeneXpert MTB/RIF assay in an intensified tuberculosis case finding survey among HIV-infected prisoners in malaysia. PLoS One 2013, 8(9):e73717.
• [34]Farhat M, Greenaway C, Pai M, Menzies D: False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 2006, 10(11):1192-1204.
• [35]Tan LH, Kamarulzaman A, Liam CK, Lee TC: Tuberculin skin testing among healthcare workers in the University of Malaya Medical Centre, Kuala Lumpur, Malaysia. Infect Control Hosp Epidemiol 2002, 23(10):584-590.
• [36]Graham NM, Nelson KE, Solomon L, Bonds M, Rizzo RT, Scavotto J, Astemborski J, Vlahov D: Prevalence of tuberculin positivity and skin test anergy in HIV-1-seropositive and -seronegative intravenous drug users. JAMA 1992, 267(3):369-373.
• [37]Portu JJ, Aldamiz-Etxebarria M, Agud JM, Arevalo JM, Almaraz MJ, Ayensa C: Tuberculin skin testing in intravenous drug users: differences between HIV-seropositive and HIV-seronegative subjects. Addict Biol 2002, 7(2):235-241.
• [38]Selwyn PA, Sckell BM, Alcabes P, Friedland GH, Klein RS, Schoenbaum EE: High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA 1992, 268(4):504-509.
• [39]World Health Organization (WHO): Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva: WHO Press; 2011.
• [40]Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH: Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet 2010, 376(9738):367-387.
• [41]World Health Organisation (WHO): Three I’s for HIV/TB Meeting Report. Intensified case-finding (ICF), isoniazid preventive therapy (IPT) and TB infection control (IC) for people living with HIV. Geneva: WHO; 2008.
• [42]World Health Organization (WHO): WHO policy on TB infection control in health-care facilities, congregate settings and households. Geneva: WHO Press; 2009.
• [43]O’Grady J, Hoelscher M, Atun R, Bates M, Mwaba P, Kapata N, Ferrara G, Maeurer M, Zumla A: Tuberculosis in prisons in sub-Saharan Africa–the need for improved health services, surveillance and control. Tuberculosis (Edinb) 2011, 91(2):173-178.
• [44]Golub JE, Mohan CI, Comstock GW, Chaisson RE: Active case finding of tuberculosis: historical perspective and future prospects. Int J Tuberc Lung Dis 2005, 9(11):1183-1203.
• [45]Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, et al.: Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010, 363(11):1005-1015.
• [46]Lawn SD, Brooks SV, Kranzer K, Nicol MP, Whitelaw A, Vogt M, Bekker L-G, Wood R: Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med 2011, 8:e1001067.
• [47]Akolo C, Adetifa I, Shepperd S, Volmink J: Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010, (1):Art. No.:CD000171.
• [48]Smieja MJ, Marchetti CA, Cook DJ, Smaill FM: Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 1999, (1):Art. No. CD001363.
• [49]Getahun H, Granich R, Sculier D, Gunneberg C, Blanc L, Nunn P, Raviglione M: Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. AIDS 2010, 24(Suppl 5):S57-S65.
• [50]Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, et al.: Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011, 365(23):2155-2166.
• [51]Churchyard G, Fielding K, Lewis J: Community-wide Isoniazid Preventive Therapy Does Not Improve TB Control among Gold Miners: The Thibela TB Study, South Africa (Abstract 150aLB). In 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012). Seattle, Washington; 2012.
• [52]Sylla L, Bruce RD, Kamarulzaman A, Altice FL: Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services. Int J Drug Policy 2007, 18(4):306-312.
• [53]World Health Organization (WHO): Policy Guidelines For Collaborative TB And HIV Services For Injecting And Other Drug Users: An Integrated Approach. Geneva: WHO Press; 2008.
• [54]Jittimanee SX, Ngamtrairai N, White MC, Jittimanee S: A prevalence survey for smear-positive tuberculosis in Thai prisons. Int J Tuberc Lung Dis 2007, 11(5):556-561.
• [55]Reid SE, Topp SM, Turnbull ER, Hatwiinda S, Harris JB, Maggard KR, Roberts ST, Kruuner A, Morse JC, Kapata N, et al.: Tuberculosis and HIV control in sub-Saharan African prisons: "thinking outside the prison cell". J Infect Dis 2012, 205(Suppl 2):S265-273.
• [56]Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC: Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO global surveillance and monitoring project. JAMA 1999, 282(7):677-686.
• [57]Cauthen GM, Pio A, ten Dam HG: Annual Risk of Tuberculous Infection. Geneva: WHO; 1988.
• [58]Maru DS, Basu S, Altice FL: HIV control efforts should directly address incarceration. Lancet Infect Dis 2007, 7(9):568-569.